Development and In-Vitro Assessment of Sustained Release Matrix Tablets of Metoprolol Succinate

Development and In-Vitro Assessment of Sustained Release Matrix Tablets of Metoprolol Succinate | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Development and In-Vitro Assessment of Sustained Release Matrix Tablets of Metoprolol Succinate Neeti Gupta, Nischal Gupta, Abhishek chaudhary This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-8014851/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract The recommended oral dosage of metoprolol succinate, a beta-blocker used to treat high blood pressure, is 25 to 100 mg once daily. This project aims to develop a sustained-release (SR) tablet containing metoprolol succinate using HPMC K100M, Carbopol 934P, and PVP K30 to maintain drug release for up to 24 hours with minimal polymer use. Fifteen batches were prepared using a 3³-factor Box-Behnken statistical design to optimize the drug release profile. The formulation of metoprolol succinate tablets (47.5 mg), equivalent to 50 mg of metoprolol tartrate, involved varying amounts of Carbopol 934P, HPMC K100M, and PVP K30, adjusting the total tablet weight to 300 mg. Tablets were produced via direct compression, and statistical analysis was conducted to assess the effects of independent variables on dependent variables. Mathematical modeling determined the optimal formulation, and Stat graphics software was employed to analyze variable relationships. The produced tablets weighed between 299.10 and 305.49 mg, with an average hardness of 6.77 ± 0.21 to 7.18 ± 0.17 kg/cm². Thickness ranged from 4.11 ± 0.01 mm to 4.32 ± 0.013 mm, and friability values were between 0.18% and 0.36%. Drug content in formulations F1 to F15 ranged from 98.01% to 102.99%, within the acceptable 90–110% range. The optimized formulation contained 110 mg of HPMC K100M, 83.70 mg of Carbopol 934P, and 23.94 mg of PVP K30. Following Hixson-Crowell release kinetics, Batch F14 closely resembled the optimized formulation, achieving a maximum release of 100.24%. This study demonstrates the feasibility of an SR matrix tablet for controlled drug release and improved bioavailability. Metoprolol succinate HPMC k 100M Carbopol-934 PVPK 30 Full Text Additional Declarations Competing interest reported. No, I have no competing financial or non-financial interests to declare. Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-8014851","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":542349409,"identity":"7c02dcaf-17fb-4575-b34d-b734289e70a6","order_by":0,"name":"Neeti Gupta","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAABBUlEQVRIiWNgGAWjYLCCBDDJfPDxnwoQzdxASANjA0gLDwNbsgHPGZAWRiK0MIC18JhJ8LYhBHACc/bm4w8e/DqcZ89+wExCcl5tNH87UMuPim04tVj2HEtsSOw7XMzDk5BsYbjteO6Mw4wNjD1nbuPUYnAjx7AhsedwYg9DwsEbiduO5TYAtTAztuHRcv/9R4gW/ocNEgfnHMudT1DLDR5giP0AapFIZpJsbKjJ3UBQy5k0wxmJDenFPDeeMRszHDuQuxGo5SBevxw//ODjjz/Weez9+R8fM9TU5c47f/jggx8VuLWAAWMbNAEwMBwGkwfwqweBP3AtdYQVj4JRMApGwYgDAN8DZdt0bmvlAAAAAElFTkSuQmCC","orcid":"","institution":"Kathmandu University","correspondingAuthor":true,"prefix":"","firstName":"Neeti","middleName":"","lastName":"Gupta","suffix":""},{"id":542349410,"identity":"f5137515-4479-495f-b1d3-683b78f8198c","order_by":1,"name":"Nischal Gupta","email":"","orcid":"","institution":"","correspondingAuthor":false,"prefix":"","firstName":"Nischal","middleName":"","lastName":"Gupta","suffix":""},{"id":542349411,"identity":"38e7dd6e-d6d5-4ea6-81e4-eed908f369bb","order_by":2,"name":"Abhishek chaudhary","email":"","orcid":"","institution":"Kathmandu University","correspondingAuthor":false,"prefix":"","firstName":"Abhishek","middleName":"","lastName":"chaudhary","suffix":""}],"badges":[],"createdAt":"2025-11-03 05:08:20","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-8014851/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-8014851/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":95656620,"identity":"4711e736-8547-4505-993c-ac705ebec997","added_by":"auto","created_at":"2025-11-11 16:19:13","extension":"pdf","order_by":1,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":696688,"visible":true,"origin":"","legend":"","description":"","filename":"neetimanuscript11.pdf","url":"https://assets-eu.researchsquare.com/files/rs-8014851/v1_covered_c944ccb1-a86a-4bd3-9483-d1a759d53a71.pdf"}],"financialInterests":"Competing interest reported. No, I have no competing financial or non-financial interests to declare.","formattedTitle":"Development and In-Vitro Assessment of Sustained Release Matrix Tablets of Metoprolol Succinate","fulltext":[],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":false,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":true,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":true,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":true,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"Metoprolol succinate, HPMC k 100M, Carbopol-934, PVPK 30","lastPublishedDoi":"10.21203/rs.3.rs-8014851/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-8014851/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003eThe recommended oral dosage of metoprolol succinate, a beta-blocker used to treat high blood pressure, is 25 to 100 mg once daily. This project aims to develop a sustained-release (SR) tablet containing metoprolol succinate using HPMC K100M, Carbopol 934P, and PVP K30 to maintain drug release for up to 24 hours with minimal polymer use. Fifteen batches were prepared using a 3\u0026sup3;-factor Box-Behnken statistical design to optimize the drug release profile. The formulation of metoprolol succinate tablets (47.5 mg), equivalent to 50 mg of metoprolol tartrate, involved varying amounts of Carbopol 934P, HPMC K100M, and PVP K30, adjusting the total tablet weight to 300 mg. Tablets were produced via direct compression, and statistical analysis was conducted to assess the effects of independent variables on dependent variables. Mathematical modeling determined the optimal formulation, and Stat graphics software was employed to analyze variable relationships. The produced tablets weighed between 299.10 and 305.49 mg, with an average hardness of 6.77\u0026thinsp;\u0026plusmn;\u0026thinsp;0.21 to 7.18\u0026thinsp;\u0026plusmn;\u0026thinsp;0.17 kg/cm\u0026sup2;. Thickness ranged from 4.11\u0026thinsp;\u0026plusmn;\u0026thinsp;0.01 mm to 4.32\u0026thinsp;\u0026plusmn;\u0026thinsp;0.013 mm, and friability values were between 0.18% and 0.36%. Drug content in formulations F1 to F15 ranged from 98.01% to 102.99%, within the acceptable 90\u0026ndash;110% range. The optimized formulation contained 110 mg of HPMC K100M, 83.70 mg of Carbopol 934P, and 23.94 mg of PVP K30. Following Hixson-Crowell release kinetics, Batch F14 closely resembled the optimized formulation, achieving a maximum release of 100.24%. This study demonstrates the feasibility of an SR matrix tablet for controlled drug release and improved bioavailability.\u003c/p\u003e","manuscriptTitle":"Development and In-Vitro Assessment of Sustained Release Matrix Tablets of Metoprolol Succinate","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2025-11-11 10:07:41","doi":"10.21203/rs.3.rs-8014851/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"f4024db2-9040-44da-afcb-f4da080c53ff","owner":[],"postedDate":"November 11th, 2025","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[],"tags":[],"updatedAt":"2025-11-11T10:07:41+00:00","versionOfRecord":[],"versionCreatedAt":"2025-11-11 10:07:41","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-8014851","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-8014851","identity":"rs-8014851","version":["v1"]},"buildId":"XKTyCvWXoU3ODBz1xrDgd","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}